The standard treatment for patients with diffuse large B-cell lymphoma (DLBCL) is based on clinical stage. Clinical and biologic prognostic factors are used to select or stratify patients enrolled ondoi:10.1007/978-3-319-08467-1_6Anastasios StathisAhmet DoganSpringer International Publishing...
lenalidomidePrimary cutaneous diffuse large B-cell lymphoma, leg type (PCDLBCL-LT) is a rare diffuse large B-cell lymphoma confined to the skin of the... Eva,Gupta,Joseph,... - 《Rare Tumors》 被引量: 4发表: 2015年 [Molecular targeted therapy in lymphoid leukemias] Leukemia-Lymphoma, Adu...
Polyclonal anti-idiotype antibodies raised in sheep have been given to four patients with B cell leukemia6,7 and to three patients with lymphoma.8 There were transient reductions in the level of circulating lymphocytes, but no long-lasting antitumor effect was seen. After each infusion, there ...
S-palmitoylation is essential for cancer development via regulating protein stability, function and subcellular location, yet the roles S-palmitoylation plays in diffuse large B-cell lymphoma (DLBCL) progression remain enigmatic. In this study, we uncove
Treatment recommendations for patients with diffuse large B-cell lymphoma (DLBCL) begin with evaluating the extent of the disease, performance status of the patient, and histologic subtypes. Treatment of localized and advanced disease varies considerably. Below is a general treatment algorithm for DLBCL...
Malignancies of B-cell origin constitute a diverse set of neoplasms that vary in B-cell subtype of origin and underlying genetic drivers. In addition, they vary widely in clinical outcome. Follicular non-Hodgkin's lymphoma (FL) or chronic lymphocytic leukemia (CLL), are indolent and incurable ...
14. Yu H, Wang X, Li J, et al. Addition of BTK inhibitor orelabrutinib to rituximab improved anti-tumor effects in B cell lymphoma. Mol Ther Oncolytics. 2021 Apr 3;21:158-170. 15. Flinsenberg TWH, et. Haematologica. 2020 Jan 31;105(2):e76-e79. ...
(Roche data on file)] and is currently standard of care for the common B-cell non-Hodgkin lymphomas (NHLs), follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL), as well as chronic lymphocytic leukemia (CLL) [2,3,4,5]. In 2015, rituximab was classified as an essential...
We describe an unusual case of severe pulmonary bullous disease developing during treatment of marginal zone B-Cell lymphoma (MALT) involving the pulmonary parenchyma. The patient originally presented with pneumonia-like symptoms along with hemoptysis and was diagnosed with MALT lymphoma after a video-...
In vivo, IHMT-EZH2-115 exhibited favorable pharmacokinetic characteristics for oral administration and demonstrated dose-dependent antitumor efficacies in two xenograft mouse models of diffuse large B-cell lymphoma cell lines harboring EZH2mutations, Pfeiffer (EZH2A677G) and Karpas-422 (EZH2Y641N). The...